United States v. Brown

636 F. App'x 640
CourtCourt of Appeals for the Sixth Circuit
DecidedJanuary 19, 2016
DocketNo. 15-5391
StatusPublished
Cited by1 cases

This text of 636 F. App'x 640 (United States v. Brown) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Brown, 636 F. App'x 640 (6th Cir. 2016).

Opinion

OPINION

JANE B. STRANCH, Circuit Judge.

Raymond Sean Brown appeals the procedural and substantive reasonableness of his 28-month sentence after pleading [641]*641guilty to receiving and distributing mis-branded drugs in interstate commerce with intent to defraud and mislead. Brown contends that the district court erred by (1) relying on the higher underlying guideline range rather than adhering to the statutorily authorized maximum sentence, (2) giving too much weight to general deterrence, and (3) failing to consider all of Brown’s arguments for a downward variance. For the reasons set forth below, we find the district court’s sentence both procedurally and substantively reasonable and, therefore, affirm.

I. BACKGROUND

Brown, a physician, owned and operated a pain management clinic in Cleveland, Tennessee, where he used Botox injections to treat patients suffering from muscle pain and spasticity. Botox is a “prescription drug” within the meaning of the Food, Drug, and Cosmetic Act due to “its toxicity or other potentiality for harmful effects.” 21 U.S.C. § 353(b)(1). The manufacture, distribution, and administration of Botox is closely regulated by United States Food and Drug Administration (FDA). To meet FDA requirements, facilities that manufacture Botox must be registered with the Secretary of the United States Department of Health and Human Services. Bo-tox packaging must comply with specific labeling standards, 21 C.F.R. 201.15(c)(1), and it may be administered only by a licensed practitioner, 21 U.S.C. § 353(b)(1). Allergan Inc. is the sole manufacturer that produces and distributes Botox approved by the FDA for sale in the United States.

In 2007, Brown began to purchase Botox from a non-FDA approved wholesale source, Canadian company Axon Medical Supplies. While all Botox is made by Al-lergan, the product sold by Axon Medical Supplies was manufactured for sale outside of the United States and contained labeling and patient information that was not in English. Between 2007 and 2012, Brown purchased at least 254 vials of unapproved, misbranded Botox, or a total of 25,400 units. This he diluted to one one-hundredth of its original strength and administered to patients without alerting them that they were receiving an unapproved drug. At this time, the average amount of reimbursement for one vial (containing 100 units) of Botox was $548.00, of which Medicare covered 80%, or approximately $438.40.

Over the course of five years, Brown submitted claims to Medicare for approximately 1,586,500 units of Botox, though he had purchased only 25,400 units, all of which were of misbranded and unapproved Botox. While Brown’s use of unapproved Botox did not result in any physical harm to his patients, he accumulated more than $7,482,968 in reimbursement checks from Medicare over the course of his fraudulent billing scheme.

In December 2012, after Brown’s extraordinarily high rate of billing for Botox treatments attracted notice and generated an investigation, federal agents seized $6,765,608.92 from two of Brown’s bank accounts. In October 2014, Brown entered an amended plea agreement in which he pleaded guilty to receiving and distributing misbranded drugs in interstate commerce with intent to defraud or mislead in violation of 21 U.S.C. § 331(c). He agreed to forfeit the seized assets and to satisfy a money judgment of $717,359.08, the outstanding amount of his violation.

The revised presentence report, filed February 27, 2015, calculated Brown’s initial advisory guideline range at 63 to 78 months imprisonment based on his offense level (26) and criminal history category (I). This underlying guideline range was lowered to comply with a statutorily author[642]*642ized maximum sentence of 36 months. 21 U.S.C. §§ 331(c), 333(a)(2). See United States Sentencing Commission, Guidelines Manual, § 5G1.1(a) (Nov. 2014) (“Where the statutorily authorized maximum sentence is less than the minimum of the applicable guideline range, the statutorily authorized maximum sentence shall be the guideline sentence”). Brown filed an objection to the portion of the revised pre-sentence report that identified no grounds for downward departure or variance. He submitted a Sentencing Memorandum, Motion for Downward Variance, and approximately 200 letters endorsing his good character, in support of his request for a sentence of probation.1

On April 2, 2015, Brown was sentenced to 28 months of imprisonment. On appeal, he challenges the procedural and substantive reasonableness of this sentence. He asserts that the district court erred by (1) “considering an underlying greater guideline range of 63-78 months rather than the applicable guidelines range of 36 months (the statutory maximum)”; (2) “giving too much weight to the factor of general deterrence”; and (3) “failing to consider all of Brown’s arguments for a downward variance under 18 U.S.C. § 3553(a).” (Appellant Br. at 11).

II. ANALYSIS

We begin our analysis of Brown’s sentence by reviewing for procedural errors, “such as failing to calculate (or improperly calculating) the Guidelines range, treating the Guidelines as mandatory, failing to consider the § 3553(a) factors, selecting a sentence based on clearly erroneous facts, or failing to adequately explain the chosen sentence — including an explanation for any deviation from the Guidelines range.” Gall v. United States, 552 U.S. 38, 51, 128 S.Ct. 586, 169 L.Ed.2d 445 (2007).

The district court’s legal conclusions regarding the Sentencing Guidelines are generally reviewed de novo. However, where a party fails to raise an objection below, our review is for plain error. U.S. v. Bostic, 371 F,3d 865, 872-73 (6th Cir.2004). “A ‘plain error’ is an error that is clear or obvious, and if it affects substantial rights, it may be noticed by an appellate court.” United States v. McIntosh, 484 F.3d 832, 836 (6th Cir.2007) (quoting United States v. Barajas-Nunez, 91 F.3d 826, 830 (6th Cir.1996)). We typically “correct a plain forfeited error that affects substantial rights only if the error seriously affects the fairness, integrity or public reputation of judicial proceedings.” Id. (internal citations omitted).

If no significant procedural errors exist, we next consider the substantive reasonableness of the sentence for abuse of discretion. Gall, 552 U.S. at 51, 128 S.Ct. 586. “An abuse of discretion occurs when a ruling is based on an error of law or a clearly erroneous finding of fact, or when the reviewing court is otherwise left with the definite and firm conviction that the district court committed a clear error of judgment.” United States v. Kumar,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kevin Prescott v. Seterus, Inc.
684 F. App'x 947 (Eleventh Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
636 F. App'x 640, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-brown-ca6-2016.